Zodasiran
Based on 1 Customer Validation
Zodasiran is a siRNA targeted to ANGPTL3 in the liver.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 95.26%
- CAS No.: 2232918-66-8
- Formule: C491H646F13N162O309P43S7
- Masse moléculaire:15564.70
-
Stockage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Activité biologique
Description
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2232918-66-8
-
Appearance Solid
-
Masse moléculaire 15564.70
-
Formule C491H646F13N162O309P43S7
-
Color White to off-white
-
SMILES
[Zodasiran]
-
Synonyms
ARO-ANG3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Protocole
-
RNA interference technology
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing gene transcription or activating RNA degradation. This mechanism was discovered in plants in 1998 by Andrew Fire and Craig Mello. Today, this phenomenon can be observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals.
Pureté et documentation
-
Fiche technique (264 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2242 KB)
Références
[1]. Rosenson RS, Gaudet D, Hegele RA, et al. Zodasiran, an RNAi Therapeutic targeted to ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024;391(10):913-925. [Content Brief]
[2]. Kamrul-Hasan ABM, Dutta D, Nagendra L, Mondal S, Bhattacharya S, Kalra S. Safety and Efficacy of the Novel RNA Interference Therapies for Hypertriglyceridemia and Mixed Hyperlipidemia Management: A Systematic Review and Meta-analysis. Endocr Pract. 2024;30(11):1103-1112. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)